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It is well known that the efficacy and safety of chemotherapeutic drugs show substantial
individual and/or population variability that can be explained, to a great extent, by genetic
factors in pharmacokinetics and pharmacodynamics (Quiñones et al., 2008; Roco et al., 2012;
Izar et al., 2013; Kessler et al., 2014; Patel, 2015; Unger et al., 2015). In the context of anticancer
drugs, polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters and
drug targets influence the pharmacokinetics and pharmacodynamics, have been shown to affect
clinical outcomes (Binkhorst et al., 2015; Newman et al., 2015). Several chemotherapeutic
agents can be more harmful to normal tissues than the targeted tumor, and their use may
result in tumor cell resistance, toxicity and occasionally secondary neoplasia. Current practices
for the dosing of therapeutic agents could be improved through the understanding of gene
variation that impacts the life of the drug inside the body. In order to better predict a
patient’s predisposition to treatment complications and poor outcomes, it is essential to consider
all candidate loci influencing response to the chemotherapeutic agents. This requires better
understanding of the metabolic pathways for activation or inactivation of these drugs, drug
interactions, age and gender sensitivities, and the impact of ethnicity and environmental factors.
As an added benefit, a more rational use of expensive treatment drugs, together with actions
to minimize patient toxic events and their consequences, would dramatically reduce medical
costs.
Pharmacogenomics is an emerging field focused on genetic variations relevant to drug
action (Evans and Relling, 2004; Maxmen, 2011; Mayer, 2014; Zhou et al., 2015). Solid
data concerning allele variants, haplotypes and their effects on gene expression, applied
to the use of chemotherapy regimens’ design and dosing has the potential to enhance
treatment outcomes. Some of the potential polymorphic candidate genes include the
CYP isozymes, transferases, dehydrogenases, deaminases, reductases, ABC transporters, drug
receptors and DNA repair enzymes (Agundez, 2004; Bruhn and Cascorbi, 2014; Roco et al.,
2014).
With this Research Topic we aim to present an updated overview of the current trends
in the experimental genetic approaches worldwide, and discuss future directions in cancer
pharmacotherapy. The scope of this issue is to collect evidence to conceive chemotherapy tailored
to each patient.
In this special edition we have five manuscripts: four reviews and one original article.
Filipski et al. (2014) discuss the use of observational studies, as well as the use adaptive
trials and next generation sequencing to achieve the required level of evidence for clinical
implementation. They propose to move the research field toward retrospective analyses, large
population studies using Electronic Medical Records, and mechanism-based evidence to propel
progress in the field. In addition, embracing new methods, such as next generation sequencing
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and pharmacogenomic adaptive clinical trials, will enrich our
knowledge about tumor biology, and change the clinical
approaches for cancer treatment. They highlight that up-to-date
pharmacogenomic studies tend to focus on either somatic or
germline mutations in isolation, but to truly optimize clinical
care both genomes need to be integrated into clinical decision
making. Agúndez et al. (2014) review the development of
clinical practice recommendations or guidelines for the clinical
use of pharmacogenomics data. They suggest that this is an
essential issue for improving drug therapy, particularly for
drugs with high toxicity and/or narrow therapeutic index,
such as anticancer agents. The few available clinical practice
guidelines for translating Pharmacogenomics are insufficient
for its application in the use of anticancer therapy. The
application of available guidelines, further implementation
with clinical feedback, plus a combination of genomics and
phenomics is urgently required. Roco and co-workers explore
the possibility for prediction of the efficacy and safety
of cisplatin treatment using a pharmacogenomic approach,
and focus primarily on DNA reparation and Glutathione
S-Transferases (GSTs) enzymes. They conclude that there
is a potential utility for pharmacogenetics in therapeutic
schemes employing cisplatin. This could be addressed through
collaborative efforts to study molecular characteristics of drug
treatment in order to develop a genetic panel for this
context.
Finally, T. Ishikawa’s mini-review and the original article of
Zocche et al. (2015) describe the use of two relevant genes in
oncology as prognostic biomarkers. Ishikawa (2014) focuses on
genetic polymorphism in the NRF2 gene, especially in the future
for individualized cancer lung cancer treatment. The author
supports the role of this gene as a mediator of cancer cell
proliferation and drug resistance, and highlight the −617C>A
change in the anti-oxidant response element (ARE)-like loci
as relevant in the attenuation of the positive feedback loop of
transcriptional activation of NRF2, leading to reduced NRF2
protein levels. As a consequence, it is considered cancer cells
will become more sensitive to therapy and less aggressive than
cancer cells harboring the wild type allele. Therefore, genetic
polymorphisms in NRF2 might serve as prognosis markers for
cancer therapy. Finally, Zocche et al. (2015) investigated the
clinical application and the Global Impact of KRAS mutation
patterns in 5-fluorouracil regimens (FOLFOX and FOLFIRI).
The study investigated the progression-free survival and overall
survival in colorectal cancer patients receiving FOLFOX
treatment with respect to KRAS mutations. They conclude that
G12D KRAS mutation was significantly associated with a poor
prognosis.
We proudly present the current Research Topic and believe it
contributes evidence for the better understanding of the genetic
basis in individual differences in response to antineoplastic
drugs, as well as suggesting potential biomarkers for treatment
prognosis.
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